Malaria remains one of the most relentless public health challenges in sub-Saharan Africa, and the medicines used to treat it, particularly artemisinin-based combination therapies, are deployed on a staggering scale across the continent. Yet the safety monitoring that should accompany this massive drug exposure is, in many settings, almost entirely silent. A new mixed-methods study from Ogun State in Southwest Nigeria has now quantified just how…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.